Searchable abstracts of presentations at key conferences in endocrinology

ea0032p1052 | Thyroid (non-cancer) | ECE2013

Serum concentrations of cholesterol and triglyceride in patients with type 2 diabetes and incident hypothyroidism

Diez Juan J , Iglesias Pedro

Background: Subclinical thyroid hypofunction and elevation of serum lipid concentrations are two factors that may act synergistically in the increase of cardiovascular risk in patients with type 2 diabetes. However, the association between subclinical hypothyroidism and dyslipidemia is a matter of debate.Objective: Our aim has been to assess whether incident hypothyroidism detected in a screening program is accompanied by elevations in the serum concentr...

ea0049ep784 | Endocrine tumours and neoplasia | ECE2017

Multidisciplinary committee on endocrine tumors: an analysis of 6-year experience

Diez Juan J , Iglesias Pedro , Alonso-Gordoa Teresa , Grande Enrique , Gajate Pablo

Aim: Multidisciplinary approach is mandatory in the management of endocrine tumors. Herein, we summarize the healthcare activity performed during the last 6 years at the multidisciplinary committee for endocrine tumors of a tertiary and University Hospital.Methods: A search of clinical-care activity of the endocrine tumors committee of our hospital from 2011 to 2016 was performed. Clinical and demographic data of all patients were recorded. The committee...

ea0056p1123 | Thyroid cancer | ECE2018

Prevalence and clinical significance of BRAFV600E mutation in patients with papillary thyroid cancer

Williams Alejandra , Santon Almudena , Pian Hector , Cristobal Eva , Iglesias Pedro , Diez Juan J

Background: The BRAFV600E mutation is the most common mutation in papillary thyroid carcinoma (PTC). Its presence has been associated with extrathyroid invasion, lymph node metastasis, and tumor recurrence. Recently, assessment of the BRAFV600E mutation status in patients with PTC has been used as a method to predict tumor aggressiveness.Objective: Our aim has been to analyze the prevalence of BRAFV60...

ea0041ep210 | Cardiovascular Endocrinology and Lipid Metabolism | ECE2016

Natural history and metabolic implications of the new hormone fibroblast growth factor 21 in uremic patients on peritoneal dialysis

Diez Juan J , Gonzalez Elena , Bajo Maria Auxiliadora , Peso Gloria Del , Grande Cristina , Rodriguez Olaia , Diaz-Almiron Mariana , Iglesiaas Pedro , Selgas Rafael

Background: Human fibroblast growth factor 21 (FGF21) is a new liver hormone that stimulate adipocyte glucose uptake and is involved in regulation of body fat.Objective: To define the natural history of FGF21 in peritoneal dialysis (PD) patients and analyze its relationship with glucose metabolism, peritoneal function, and residual renal function (RRF).Methods: We studied 48 uremic patients undergoing PD. Patients were evaluated at...

ea0037ep1030 | Thyroid (non-cancer) | ECE2015

Relationship between thyroid function tests and all-cause mortality in patients on peritoneal dialysis: a prospective analysis

Diez Juan J , Romero-Perez Sara , Bajo Maria A , Iglesias Pedro , Grande Cristina , Peso Gloria Del , Madero Rosario , Ossorio Marta , Selgas Rafael

Background: Alterations in thyroid function tests results in patients on peritoneal dialysis (PD) might represent a risk factor for cardiovascular disease (CVD) and mortality.Objective: To investigate the relationship of serum TSH, free thyroxine (FT4), and triiodothyronine (T3) concentrations with incident CVD and mortality in PD patients.Methods: Prospective study including all patients attending our PD unit...